LINZESS helps you have more frequent and complete bowel movements and helps relieve belly pain and overall abdominal symptoms* (pain, discomfort, and bloating) associated with IBS-C. *Abdominal symptoms were studied in combination, not individually.

LINZESS contains linaclotide-coated beads in hard gelatin capsules. LINZESS is available as 145 mcg and 290 mcg capsules for oral administration. The inactive ingredients of LINZESS capsules include: calcium chloride dihydrate, L-leucine, hypromellose, microcrystalline cellulose, gelatin, and titanium dioxide.

Linzess has an average rating of 6.4 out of 10 from a total of 216 reviews for the treatment of Irritable Bowel Syndrome with Constipation. 54% of reviewers reported a positive experience, while 29% reported a negative experience.

Linzess belongs to a class of medications called guanylate cyclase-C agonists. It comes as an oral capsule. Linzess is available in strengths of 72 micrograms (mcg), 145 mcg, and 290 mcg.

LINZESS can cause serious side effects including diarrhea, which can sometimes be severe. Diarrhea is the most common side effect, and often begins within the first 2 weeks of treatment. Stop taking LINZESS and call your doctor right away if you experience severe diarrhea while taking LINZESS.

Linzess is only available as a brand-name drug. It does not come in a generic version. A generic drug is an exact copy of the active drug in a brand-name medication. Generics tend to cost less than brand-name drugs.

AstraZeneca and Ironwood are jointly responsible for the development and commercialization of linaclotide in China , with AstraZeneca primarily responsible for local operational execution. Linaclotide is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways based on nonclinical studies.

Developed and marketed by AbbVie and Ironwood in the US, LINZESS was previously approved to treat irritable bowel syndrome with constipation or chronic idiopathic constipation in adult patients.

LINZESS can cause serious side effects including diarrhea, which can sometimes be severe. Diarrhea is the most common side effect, and often begins within the first 2 weeks of treatment. Stop taking LINZESS and call your doctor right away if you experience severe diarrhea while taking LINZESS.

LINZESS List Price. The list price, also known as the Wholesale Acquisition Cost (WAC),* for LINZESS® is $490.63 a month (as of January 2022).

About Ironwood Pharmaceuticals We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

AstraZeneca and Ironwood are jointly responsible for the development and commercialization of linaclotide in China , with AstraZeneca primarily responsible for local operational execution. Linaclotide is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways based on nonclinical studies.

About 90% of LINZESS prescriptions have an out-of-pocket cost between $0-$10 per month depending on state plan. About 80% of LINZESS prescriptions have an out-of-pocket cost between $0-$50 per month††, depending on coverage phase.

Conclusions: long-term linaclotide treatment in patients with C-IBS is effective and safe in the clinical setting.

Linzess is only available as a brand-name drug. It does not come in a generic version. A generic drug is an exact copy of the active drug in a brand-name medication. Generics tend to cost less than brand-name drugs.

LINZESS can cause serious side effects including diarrhea, which can sometimes be severe. Diarrhea is the most common side effect, and often begins within the first 2 weeks of treatment. Stop taking LINZESS and call your doctor right away if you experience severe diarrhea while taking LINZESS.